Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in…
Posted: January 27, 2025 at 2:49 am
FORT LEE, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the results from a post-hoc analysis of the international CARES-310 study evaluating camrelizumab plus rivoceranib vs. sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of viral and non-viral etiology. The post-hoc analysis will be presented in a poster at the 2025 American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium (ASCO GI) on January 24.
Posted in Global News Feed
Comments Off on Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in…
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Posted: January 27, 2025 at 2:49 am
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
More:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Posted in Global News Feed
Comments Off on Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
Posted: January 27, 2025 at 2:49 am
PRESS RELEASE
More:
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
Posted in Global News Feed
Comments Off on AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…
Posted: January 27, 2025 at 2:49 am
Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data
Read the original:
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated...
Posted in Global News Feed
Comments Off on Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular…
Posted: January 27, 2025 at 2:49 am
Basel, 27 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (delandistrogene moxeparvovec), the first approved gene therapy for the treatment of individuals with Duchenne muscular dystrophy. Two years after treatment with Elevidys, statistically significant and clinically meaningful improvements were observed across three key motor function measures of NSAA, TTR and 10MWR, when compared to a pre-specified propensity-weighted untreated external control group.* Functional differences between individuals treated with Elevidys and those in the external control group increased between one and two years after dosing. Together, these results demonstrate consistent, sustained benefit in favour of Elevidys.
Follow this link:
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular...
Posted in Global News Feed
Comments Off on Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular…
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Posted: January 27, 2025 at 2:49 am
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
See the original post here:
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Posted in Global News Feed
Comments Off on FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of…
Posted: January 27, 2025 at 2:49 am
Cambridge, UK, 27 January 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has appointed Dr Heather Preston as new Non-Executive Chair, and has secured further funding to progress its lead programme in Huntington’s Disease. This brings on board pharmaceutical investor Ono Ventures Investment, joined by existing investors, Takeda Ventures, SV Health Investors’ Dementia Discovery Fund and Epidarex Capital.
See the original post here:
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of...
Posted in Global News Feed
Comments Off on Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of…
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Posted: January 27, 2025 at 2:49 am
Lausanne (Switzerland), January 27, 2025 — AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S.
Here is the original post:
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Posted in Global News Feed
Comments Off on AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation
Posted: January 27, 2025 at 2:49 am
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025.
View original post here:
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation
Posted in Global News Feed
Comments Off on Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation
